December 14, 2020 7:54am

Vaccine shipments also begin “truckin” sentiment

Pre-open indications: 6 BUYs, 4 SELLs

News:  Brainstorm Cell Therapeutics (BCLI) initiated a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the recently concluded pivotal P3 clinical trial and meet specific eligibility requirements (pre-market indication +$0.82 or +17.56%)

What I provide is a trusted source of share pricing intelligence that ensures that investors are kept apprised of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets

A pre-open briefing on what you need to know in the session ahead!

Dow futures are UP +0.84% (251 points), S&P futures are UP +0.79% (+29 points) and NASDAQ futures are UP +0.62% (+77 points)

 

U.S. stock futures moved higher early Monday as markets indicated a rebound;

European stocks traded higher as negotiations continue between the U.K. and EU on a post-Brexit trade deal;

Asia-Pacific markets were mixed, as investors in the region react to the approval of Pfizer’s (PFE) Covid-19 vaccine.

 

Data Docket: Monday’s a bust but, there is a batch of economic data beginning Tuesday and Wednesday’s; Federal Reserve’s final Federal Open Market Committee (FOMC) meeting is on Wednesday, the U.S. Commerce Department will also release of November retail sales report

 

Henry’omics:

Another day on the roller-coaster ...

A “could or possible” condition for sentiment for Monday, a bipartisan stimulus plan could be introduced in Congress, but split into two parts in order to improve its chances of approval; part one – includes jobless monies and small business support and part two- includes liability protections and state aid … dream on but, has to be written!

The U.S. has begun to ship the doses from a Pfizer (PFE) facility in Michigan to hundreds of distribution centers across the country. The FDA is also slated to publish their assessment on Moderna’s (MRNA) vaccine this week as negotiations over a fiscal aid dragged on.” <CNBC>

 

An Update: RegMed/Cell and Gene Therapy Earnings Scorecard Q3/20 LPS Results https://www.regmedinvestors.com/articles/11628     

 

Friday’s night’s recap: RegMed Investors’ (RMi) closing bell: sentiment takes a dive … https://www.regmedinvestors.com/articles/11675

with a market response to risks of a government shutdown as senators threaten to hold up funding bill”

  • The Nasdaq closed DOWN -27.94 points (-0.23%);
  • The IBB closed up +0.25% and XBI closed down -0.06%
  • Sector volume was LOW with 8 of the 13-upside having higher than the 3-month average volume with the increased volume of 7 of 20-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +0.79 points or +3.51% at 23.31;
  • Friday’s percentage (%) of the 13-upside were +0.27% (BLFS) to +51.62% (SLDB) while the 20-downside ranges from -0.35% (BLUE) to -21.53% (SGMO);

Q4:

  • Q4’s December, so far: 1 neutral, 3 negative and 5 positive closes
  • Q4’s November: 16 positive and 3 negative closes
  • Q4’s October: 1 neutral, 11 positives with 1 negative closes
  • Q3: July through September: 1 neutral, 28 positive and 34 negative closes with 2 holidays

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell:

Biostage (BSTG) closed flat again at $1.35 with 83 shares traded after Thursday’s 337 shares traded, Wednesday’s flat with 384 shares traded, Tuesday’s at $1.35 with 761 shares traded and last Monday’s -$0.07 to $1.35 with 5,098 shares traded.

  • Question#1: NEVER forget, lawyers for the estate of a deceased individual filed a civil suit in Suffolk Superior Court in Boston, Mass. DO these MULTIPLE issues listed over months contribute to the repricing of share value going forward?
  • Question#2: Biostage has to INDEMNIFY Harvard BIO (HBIO) as a result of this litigation; but at what costs going forward in this product liability legal proceeding?

 

BUY from SELL:

BioLife Solutions (BLFS) close up +$0.11 to $40.58 after Thursday’s $40.47, Wednesday’s $38.09, Tuesday’s $37.23, and Monday’s $39.88 with a POSITIVE +$0.42 or +1.03% aftermarket indication, a 52-week high of $40.79 and a low of $7.37 and a short percentage (%) of float of 4.02%n;

Cellectis SA (CLLS) closed down -$0.71 to $29.51 after Thursday’s $30.22, Wednesday’s $27.74, Tuesday’s $29.88 and last Monday’s $30.119 with a POSITIVE +$0.49 or +1.66% pre-market indication a 52-week change of +73.59 with a 52-week high of $30.70 and a low of $7.32;

Homology Medicine (FIXX) closed up +$0.35 to $10.23 after Thursday’s $9.88, Wednesday’s $9.92, Tuesday’s $9.34, and Monday’s $9.61 with a POSITIVE +$0.52 or +5.08% aftermarket indication;

Sage Therapeutics (SGMO) closed down -$0.63 to $69.04 after Thursday’s $69.67, Wednesday’s $69.19 Tuesday’s $70.85, and Monday’s $72.02 with a POSITIVE +$0.19 or +1.55% aftermarket indication;

Sangamo Therapeutics (SGMO) closed down -$3.37 to $12.28 after Thursday’s $15.65, Wednesday’s $10.23, Tuesday’s $9.68, and Monday’s $9.28 with a POSITIVE +$0.19 or +3.39% aftermarket indication, a 52-week change of +46.71%, a 52-week high of $15.69 and a low of $4.81 with a short percentage (%) of float of -14.28%;

 

BUY on News:

Brainstorm Cell Therapeutics (BCLI) closed down -$0.08 (Friday) to $4.67; news (listed above) this a.m.  offers up a POSITIVE +$0.82 or +17.56% pre-market indication;

 

Maintaining SELL:

CRISPER Therapeutics (CRSP) closed down -$5.85 to $148.41 after Thursday’s +$7.63 to $154.26, Wednesday’s +$0.16, Tuesday’s -$3,25 and Monday’s +$2.18 with a NEGATIVE -$0.40 or -0.94% aftermarket indication, a 52-week change of +123.74%, a 52-wwek high of $163.56 and a low of $32.30 with a short percentage (%) of float of -6.92;

Editas Medicine (EDIT) closed down -$4.92 to $61.92 after Thursday’s +$16.26 to $66.84, Wednesday’s +$7.40, Tuesday’s +$4.13 and Monday’s +$4.56 with a NEGATIVE -$1.97 or -3.18% aftermarket indication, a 52-week change of +98.91%, a 52-week high of $67.27 and low of $14.01 with a short percentage (%) of float of -17.75%;

Solid Biosciences (SLDB) closed up +$1.91 to $5.61 following a $90 M private placement after Thursday’s $3.70, Wednesday’s +$3.63, Tuesday’s +$3.68 and Monday’s +$3.51 with a NEGATIVE -$0.19 or -3.39% aftermarket indication,

 

The BOTTOM LINE: Caution is STILL warranted; investors will be measuring updates on the Covid-19 vaccine rollout while the coronavirus stimulus stalemate in Washington.

As I have been saying, “a storm is coming” and “the sector has been trading water”.

Reiterating, “I am NOT always the naysayer as contrarian thinking that realizes foresight can perceive hidden opportunities and seize them at just the right moment.”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.